Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
FUSN Stock Price Chart Interactive Chart >
FUSN Price/Volume Stats
| Current price | $8.56 | 52-week high | $13.89 |
| Prev. close | $8.86 | 52-week low | $6.61 |
| Day low | $8.49 | Volume | 42,644 |
| Day high | $8.81 | Avg. volume | 56,092 |
| 50-day MA | $8.50 | Dividend yield | N/A |
| 200-day MA | $9.81 | Market Cap | 368.25M |
Fusion Pharmaceuticals Inc. (FUSN) Company Bio
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.
Latest FUSN News From Around the Web
Below are the latest news stories about Fusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate FUSN as an investment opportunity.
Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business DevelopmentFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development. |
Fusion Pharmaceuticals to Participate in Upcoming Investor ConferencesFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences. |
We Think Fusion Pharmaceuticals (NASDAQ:FUSN) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply ProductionFusion and TRIUMF to collaborate to produce actinium based on technology developed by TRIUMF HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation |
Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business UpdateFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments. |
FUSN Price Returns
| 1-mo | 3.01% |
| 3-mo | 6.20% |
| 6-mo | -15.42% |
| 1-year | -30.24% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.15% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...